Head-to-Head Review: BioNTech (NASDAQ:BNTX) Vs. Ocugen (NASDAQ:OCGN)

Ocugen ( NASDAQ:OCGN – Get Your Free Report ) and BioNTech ( NASDAQ:BNTX – Get Your Free Report ) are both medical companies, but which is the better business? We’ll compare the two companies based on their risk strength, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.

return

This table compares Ocugen and BioNTech’s net margins, return on equity and return on assets.

Internal and institutional ownership

10.3% of Ocugen shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 4.3% of Ocugen shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and big money managers believe a stock will outperform the market over the long term.

Analyst ratings

This is a summary of current ratings and recommendations for Ocugen and BioNTech as reported by MarketBeat.

Ocugen currently has a consensus target price of $6.00, indicating a potential upside of 440.54%. BioNTech has a consensus target price of $124.54, indicating a potential upside of 10.92%. Given Ocugen’s stronger consensus rating and higher possible upside, equities analysts plainly believe Ocugen is more favorable than BioNTech.

Earnings and Rating

This table compares Ocugen and BioNTech’s revenue, earnings per share and valuation.

BioNTech has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Risk and volatility

Ocugen has a beta of 3.69, suggesting that its stock price is 269% more volatile than the S&P 500. Comparatively, BioNTech has a beta of 0.23, suggesting that its stock price is 77% less volatile more volatile than the S&P 500.

Summary

BioNTech beats Ocugen on 10 of the 15 factors compared between the two stocks.

About Ocugen

(Get a free report)

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of novel gene and cell therapies and vaccines that improve patient health. The company’s product portfolio includes OCU400, a novel gene therapy candidate that restores retinal integrity and functions in a number of genetically diverse inherited retinal diseases, currently in Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leprosy . congenital amaurosis; OCU410, a Phase 1/2 gene therapy for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a Phase 1/2 gene therapy for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein in preclinical development for the treatment of diabetic macular edema, diabetic retinopathy and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage currently in Phase 3 trials for the repair of knee cartilage injuries in adults. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a tetravalent seasonal influenza vaccine; and OCU520, a combination quadrivalent seasonal influenza and COVID-19 vaccine. Has collaborative agreements with the National Institute of Allergy and Infectious Diseases for early clinical trials for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for the manufacture of modifying product candidates for gene therapy. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

About BioNTech

(Get a free report)

BioNTech SE, a biotechnology company, develops and markets immunotherapies for cancer and other infectious diseases. The Company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advanced melanoma; BNT112 which is in phase I/IIa clinical trial for prostate cancer; BNT113, which is in phase II clinical trial for the treatment of HPV 16+ head and neck cancers; BNT114 for treating triple-negative breast cancer; BNT115, which is in phase I clinical trials in ovarian cancer; and BNT116, which is in phase I clinical trial for non-small cell lung cancer. It is developing BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 which is in phase I clinical trial for multiple solid tumors; BNT141 and BNT142 which are in Phase I clinical trials to treat multiple solid tumors; BNT151, BNT152 and BNT153 to treat solid tumors; BNT211 for treating multiple solid tumors and BNT221 for pancreatic cancer and other cancers; BNT311 which is in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trials to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trials to treat ovarian cancer and Phase I/II clinical trials to treat multiple solid tumors. It is developing BNT321, an IgG1 monoclonal antibody in phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulatory product in phase I clinical trial candidate for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2 and other infectious diseases. Has collaborations with Genentech, Inc.; Sanofi SA; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics SA BioNTech SE was founded in 2008 and is based in Mainz, Germany.

Get news and reviews for Ocugen Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ocugen and related companies with MarketBeat.com’s FREE daily email newsletter.